Interpretation of expert consensus on the prevention and treatment of multiple myeloma related venous thromboembolism in China(2022)
-
摘要: 多发性骨髓瘤(MM)是一种浆细胞克隆性增殖的恶性疾病。静脉血栓栓塞症(VTE)是MM常见的并发症之一，关键在于预防、早期诊断和治疗，但我国一直以来缺乏更进一步规范MM相关VTE防治的共识。结合国内外研究和指南，中华医学会血液学分会浆细胞疾病学组和血栓与止血学组共同制定了《多发性骨髓瘤相关静脉血栓栓塞症防治中国专家共识(2022年版)》。为更好地指导临床实践，文章拟对该共识的诊断部分、风险评估部分、分层预防部分(包括肾功能不全和血小板减少患者)和治疗部分进行解读。Abstract: Multiple myeloma (MM) is a malignant disease characterized by the clonal proliferation of plasma cells. Venous thromboembolism (VTE) is one of the common complications of MM, and the key is prevention, early diagnosis, and early treatment. However, there has been a lack of relevant consensus on further standardizing the prevention and treatment of MM-related VTE in China. Combined with domestic and foreign research and guidelines, the Plasma Cell Disease Group and the Thrombosis and Hemostasis Group of the Hematology Branch of the Chinese Medical Association jointly formulated the "Expert Consensus on the Prevention and Treatment of Multiple Myeloma-related Venous Thromboembolism in China (2022 edition)". To better guide clinical practice, this paper intends to interpret the diagnostic part, the risk assessment part, the stratified prevention part (including patients with renal insufficiency and thrombocytopenia), and the treatment part of this consensus.
-
Key words:
- multiple myeloma /
- venous thromboembolism /
- prevention /
- treatment
-
-
[1] 中华医学会血液学分会浆细胞疾病学组, 中华医学会血液学分会血栓与止血学组. 多发性骨髓瘤相关静脉血栓栓塞症防治中国专家共识(2022年版)[J]. 中华血液学杂志, 2022, 43(9): 726-731.
[2] Geersing GJ, Zuithoff NP, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis[J]. BMJ, 2014, 348: g1340. doi: 10.1136/bmj.g1340
[3] Geersing GJ, Erkens PM, Lucassen WA, et al. Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study[J]. BMJ, 2012, 345: e6564. doi: 10.1136/bmj.e6564
[4] Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias[J]. Semin Thromb Hemost, 2003, 29(5): 467-471. doi: 10.1055/s-2003-44554
[5] Horváth-Puhó E, Suttorp MM, Frederiksen H, et al. Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma[J]. Clin Epidemiol, 2018, 10: 1371-1380. doi: 10.2147/CLEP.S172306
[6] Li A, Wu Q, Luo SH, et al. Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma[J]. J Natl Compr Canc Netw, 2019, 17(7): 840-847. doi: 10.6004/jnccn.2018.7273
[7] Sanfilippo KM, Luo SH, Wang TF, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score[J]. Am J Hematol, 2019, 94(11): 1176-1184. doi: 10.1002/ajh.25603
[8] Swan D, Rocci A, Bradbury C, et al. Venous thromboembolism in multiple myeloma-choice of prophylaxis, role of direct oral anticoagulants and special considerations[J]. Br J Haematol, 2018, 183(4): 538-556. doi: 10.1111/bjh.15684
[9] Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis[J]. Med J Aust, 2004, 181(9): 492-497. doi: 10.5694/j.1326-5377.2004.tb06407.x
[10] Fotiou D, Gavriatopoulou M, Terpos E. Multiple myeloma and thrombosis: prophylaxis and risk prediction tools[J]. Cancers(Basel), 2020, 12(1): 191.
[11] Wiggins BS, Dixon DL, Neyens RR, et al. Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week[J]. J Am Coll Cardiol, 2020, 75(11): 1341-1350.
[12] Streiff MB, Holmstrom B, Angelini D, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(11): 1289-1303. doi: 10.6004/jnccn.2018.0084
[13] Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma[J]. Leukemia, 2008, 22(8): 1485-1493. doi: 10.1038/leu.2008.131
[14] Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure[J]. N Engl J Med, 2001, 345(25): 1801-1808. doi: 10.1056/NEJMoa010323
[15] Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer[J]. Lancet Oncol, 2016, 17(10): e452-e466. doi: 10.1016/S1470-2045(16)30369-2
[16] Susen S, Tacquard CA, Godon A, et al. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring[J]. Crit Care, 2020, 24(1): 364. doi: 10.1186/s13054-020-03000-7
[17] Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease[J]. Kidney Int, 2020, 97(4): 664-675. doi: 10.1016/j.kint.2019.11.027
[18] Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma[J]. Blood, 2005, 106(12): 3777-3784. doi: 10.1182/blood-2005-03-1173
-
计量
- 文章访问数: 776
- PDF下载数: 408
- 施引文献: 0
下载: